THEMIS MEDICARE Latest Share Price (THEMISMED)
TODAY IN ONE LINE
THEMISMED fell 2.9% on light volume, lagging Nifty's -0.3% move.
With a market cap of ₹1,187.17 Cr., it trades at a P/E of 30.51. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
THEMIS MEDICARE flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Expensive ValuationTrading at a high P/E ratio of 950.0x
- ●Promoter SellingPromoter holding decreased by 67.10% QoQ
Latest THEMIS MEDICARE News
What changed recently?
Recent events, corporate actions, and announcements.
THEMIS MEDICARE valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for THEMIS MEDICARE, framed against the sector median so the premium or discount is obvious at a glance.
THEMIS MEDICARE trades at a P/E of 30.51× and P/B of 3.06×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
THEMIS MEDICARE technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for THEMIS MEDICARE — derived from the latest tape, not yesterday's close.
THEMIS MEDICARE last traded at ₹128.25 with an intraday range of ₹126.16–₹132.02 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹128.25| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 143.18 | +14.93 | +11.64% |
| R3 | 137.32 | +9.07 | +7.07% |
| R2 | 134.67 | +6.42 | +5.01% |
| R1 | 131.46 | +3.21 | +2.50% |
| PIVOT | 128.81 | 0.56 | 0.44% |
| CURRENT | 128.25 | — | — |
| S1 | 125.60 | -2.65 | -2.07% |
| S2 | 122.95 | -5.30 | -4.13% |
| S3 | 119.74 | -8.51 | -6.64% |
| S4 | 113.88 | -14.37 | -11.20% |
THEMISMED is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹128.71–₹132.02
Trading Below opening range, showing Bearishness
THEMIS MEDICARE financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for THEMIS MEDICARE — consolidated or standalone — with margins, YoY growth and key ratios inline.
THEMIS MEDICARE reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,187.17 Cr. and reported EPS of ₹3.12.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 406 | 342 ▼ 15.6% |
| Sales Growth YoY %Derived | 6.22% | -15.60% |
| Other Income | 5 | 9 ▲ 100.5% |
| Total Income | 410 | 352 ▼ 14.3% |
| 132 | 129 ▼ 1.9% | |
| Gross ProfitDerived | 274 | 213 ▼ 22.2% |
| Gross Margin %Derived | 67.45% | 62.17% |
| 224 | 212 ▼ 5.4% | |
| EBITDA (Operating Profit)Derived | 49 | 0 ▼ 99.2% |
| OPM %Derived | 12.10% | 0.11% |
| 20 | 20 ▲ 0.9% | |
| Profit Before Tax (PBT) | 34 | -12 ▼ 135.9% |
| 10 | 1 ▼ 92.0% | |
| Effective Tax %Derived | 29.16% | -6.47% |
| Total Profit for Period | 30 | 1 ▼ 96.2% |
| Less: Non-controlling Interests | -0 | -0 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 30 | 1 ▼ 96.2% |
| Net Profit Margin %Derived | 7.36% | 0.33% |
| PAT Growth YoY %Derived | -31.46% | -96.17% |
| Earnings Per Share (EPS ₹) | 3.24 | 0.12 ▼ 96.3% |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 0.1% |
| Share of Profit from Associates/JVs | 6 | 14 ▲ 137.1% |
| Other Comprehensive Income (Net of Tax) | -0 | -1 ▼ 131.9% |
| Total Expenses (incl. D&A & Interest) | 376 | 364 ▼ 3.4% |
| Material Cost % of RevenueDerived | 18.82% | 16.74% |
| Employee Cost % of RevenueDerived | 23.77% | 27.33% |
| Other Cost % of RevenueDerived | 31.59% | 34.73% |
| Interest Coverage (x)Derived | 3.90x | -0.93x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 212 | 184 ▼ 13.2% | 202 ▲ 9.7% | 231 ▲ 14.4% | 395 ▲ 71.1% | 354 ▼ 10.2% | 382 ▲ 7.7% | 406 ▲ 6.2% | 342 ▼ 15.6% | |
| Sales Growth YoY %Derived | — | -13.20% | 9.71% | 14.43% | 71.07% | -10.21% | 7.74% | 6.22% | -15.60% | |
| Other Income | 3 | 3 ▼ 11.4% | 3 ▲ 29.9% | 4 ▲ 4.5% | 7 ▲ 80.6% | 12 ▲ 75.9% | 5 ▼ 58.7% | 5 ▼ 1.8% | 9 ▲ 100.5% | |
| Total Income | 215 | 186 ▼ 13.2% | 205 ▲ 10.0% | 234 ▲ 14.3% | 401 ▲ 71.2% | 366 ▼ 8.8% | 387 ▲ 5.7% | 410 ▲ 6.1% | 352 ▼ 14.3% | |
72 | 68 ▼ 4.7% | 63 ▼ 7.5% | 79 ▲ 24.4% | 148 ▲ 88.5% | 118 ▼ 20.1% | 137 ▲ 15.5% | 132 ▼ 3.5% | 129 ▼ 1.9% | ||
| Gross ProfitDerived | 140 | 115 ▼ 17.6% | 138 ▲ 19.9% | 152 ▲ 9.9% | 246 ▲ 62.1% | 236 ▼ 4.3% | 245 ▲ 3.9% | 274 ▲ 11.6% | 213 ▼ 22.2% | |
| Gross Margin %Derived | 66.15% | 62.83% | 68.66% | 65.94% | 62.46% | 66.59% | 64.19% | 67.45% | 62.17% | |
115 | 113 ▼ 1.6% | 103 ▼ 9.2% | 103 ▼ 0.1% | 151 ▲ 47.0% | 169 ▲ 11.7% | 194 ▲ 14.9% | 224 ▲ 16.0% | 212 ▼ 5.4% | ||
| EBITDA (Operating Profit)Derived | 25 | 2 ▼ 90.9% | 36 ▲ 1464.5% | 49 ▲ 38.8% | 96 ▲ 93.2% | 67 ▼ 29.5% | 52 ▼ 23.6% | 49 ▼ 4.8% | 0 ▼ 99.2% | |
| OPM %Derived | 11.82% | 1.24% | 17.69% | 21.46% | 24.24% | 19.04% | 13.49% | 12.10% | 0.11% | |
19 | 20 ▲ 2.7% | 21 ▲ 6.8% | 21 ▲ 0.5% | 18 ▼ 14.1% | 20 ▲ 9.9% | 22 ▲ 7.8% | 20 ▼ 7.7% | 20 ▲ 0.9% | ||
| Profit Before Tax (PBT) | 9 | -15 ▼ 270.0% | 18 ▲ 220.9% | 32 ▲ 77.3% | 84 ▲ 163.4% | 59 ▼ 29.8% | 35 ▼ 41.2% | 34 ▼ 2.6% | -12 ▼ 135.9% | |
0 | -2 ▼ 1904.9% | 2 ▲ 213.9% | 6 ▲ 168.9% | 22 ▲ 297.7% | 16 ▼ 30.2% | 10 ▼ 36.5% | 10 ▼ 0.8% | 1 ▼ 92.0% | ||
| Effective Tax %Derived | 1.16% | 12.36% | 11.65% | 17.67% | 26.67% | 26.51% | 28.64% | 29.16% | -6.47% | |
| Total Profit for Period | 11 | -11 ▼ 195.8% | 25 ▲ 330.3% | 36 ▲ 44.1% | 73 ▲ 104.1% | 57 ▼ 21.9% | 44 ▼ 23.5% | 30 ▼ 31.5% | 1 ▼ 96.2% | |
| Less: Non-controlling Interests | -0 | -0 ▲ 71.1% | -0 ▲ 99.5% | -0 ▲ 0.0% | -0 ▲ 0.0% | -0 ▼ 100.0% | -0 ▼ 50.0% | -0 ▲ 33.3% | -0 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 11 | -11 ▼ 195.1% | 25 ▲ 330.7% | 36 ▲ 44.1% | 73 ▲ 104.1% | 57 ▼ 21.9% | 44 ▼ 23.5% | 30 ▼ 31.5% | 1 ▼ 96.2% | |
| Net Profit Margin %Derived | 5.34% | -5.85% | 12.29% | 15.48% | 18.47% | 16.06% | 11.40% | 7.36% | 0.33% | |
| PAT Growth YoY %Derived | — | -195.08% | 330.71% | 44.07% | 104.13% | -21.93% | -23.51% | -31.46% | -96.17% | |
| Earnings Per Share (EPS ₹) | 1.23 | -1.17 ▼ 195.1% | 2.70 ▲ 330.8% | 3.89 ▲ 44.1% | 7.92 ▲ 103.6% | 6.18 ▼ 22.0% | 4.73 ▼ 23.5% | 3.24 ▼ 31.5% | 0.12 ▼ 96.3% | |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 0.0% | 9 ▲ 0.1% | 9 ▲ 0.0% | 9 ▲ 0.1% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.1% | |
| Share of Profit from Associates/JVs | 3 | 2 ▼ 12.5% | 9 ▲ 292.7% | 9 ▲ 6.4% | 11 ▲ 19.7% | 14 ▲ 20.1% | 19 ▲ 38.1% | 6 ▼ 68.5% | 14 ▲ 137.1% | |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▲ 62.1% | -0 ▼ 51.4% | -0 ▼ 471.0% | -0 ▲ 16.9% | -0 ▼ 27.6% | -1 ▼ 71.4% | -0 ▲ 59.9% | -1 ▼ 131.9% | |
| Total Expenses (incl. D&A & Interest) | 206 | 201 ▼ 2.3% | 187 ▼ 7.1% | 202 ▲ 8.2% | 317 ▲ 56.7% | 307 ▼ 3.2% | 352 ▲ 14.6% | 376 ▲ 7.0% | 364 ▼ 3.4% | |
| Material Cost % of RevenueDerived | 25.16% | 26.79% | 25.49% | 29.45% | 28.80% | 27.11% | 22.18% | 18.82% | 16.74% | |
| Employee Cost % of RevenueDerived | 21.09% | 24.87% | 21.96% | 17.34% | 13.17% | 18.67% | 21.59% | 23.77% | 27.33% | |
| Other Cost % of RevenueDerived | 33.24% | 36.72% | 29.01% | 27.14% | 25.05% | 28.89% | 29.11% | 31.59% | 34.73% | |
| Interest Coverage (x)Derived | 1.48x | -0.48x | 2.13x | 3.22x | 9.82x | 5.96x | 4.19x | 3.90x | -0.93x |
THEMIS MEDICARE segment analysis : revenue and profit mix.
Disclosed business segments at THEMIS MEDICARE with their share of revenue and profit, switchable between consolidated and standalone reporting.
THEMIS MEDICARE discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for THEMIS MEDICARE.
Our AI distills the core fundamental drivers supporting THEMIS MEDICARE, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
THEMIS MEDICARE's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 40 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
THEMIS MEDICARE peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — THEMIS MEDICARE is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
THEMIS MEDICARE chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for THEMIS MEDICARE — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
THEMIS MEDICARE delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for THEMIS MEDICARE over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in THEMIS MEDICARE stood at 46.8% of traded volume, against a 20-day average of 46.2%.
THEMIS MEDICARE announcements: results, concalls, ratings, M&A.
Filings THEMIS MEDICARE sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
THEMIS MEDICARE files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 74 documents below.
Copy of Newspaper Publication
Themis Medicare Limited has informed the Exchange about Copy of Newspaper Publication for Notice of 56th AGM scheduled on 30th September, 2026.
Shareholders meeting
Themis Medicare Limited has informed the Exchange regarding Notice of 56th Annual General Meeting to be held on September 30, 2026
Spurt in Volume
Significant increase in volume has been observed in Themis Medicare Limited. The Exchange, in order to ensure that investors have latest relevant…
Spurt in Volume
Significant increase in volume has been observed in Themis Medicare Limited. The Exchange, in order to ensure that investors have latest relevant…
General Updates
Themis Medicare Limited has informed the Exchange about General Updates -Change Of Company Secretary / Compliance Officer's E-Mail ID and updation of…
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
THEMIS MEDICARE dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue THEMIS MEDICARE has declared, sequenced by announce and record date.
THEMIS MEDICARE corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About THEMIS MEDICARE: business, sector, key facts.
What THEMIS MEDICARE does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
THEMIS MEDICARE operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: THEMISMED, BSE: 530199.
Themis Medicare Limited is a pharmaceutical company with a significant presence in India and international markets. Its core business revolves around the manufacture and sale of pharmaceutical products, encompassing both Active Pharmaceutical Ingredients (APIs) and finished formulations. This broad portfolio allows them to cater to a wide range of therapeutic needs.
The company's product offerings span numerous therapeutic areas, reflecting a diverse and comprehensive approach to pharmaceutical development and distribution. Key therapeutic categories include anti-tuberculosis and anti-malarial medications, addressing significant global health challenges. They also produce formulations for cardiology, pain management, and anti-infectives, demonstrating a focus on common and critical health concerns.
Furthermore, Themis Medicare's product line extends to haematinics (agents that increase red blood cell production), health and nutrition supplements, anaesthetics, gynaecological medications, and orthopedic pharmaceuticals. This extensive range indicates a commitment to providing a wide array of solutions across diverse medical specialties. The inclusion of anti-inflammatory drugs further broadens their reach within the common therapeutic landscape.
Established in 1952 and headquartered in Mumbai, India, Themis Medicare Limited has a long history within the pharmaceutical industry. Initially known as Themis Chemicals, the company rebranded to its current name in 2001, reflecting its evolution and growth. Their long-standing presence in the market suggests a significant level of experience and established industry connections.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about THEMIS MEDICARE (THEMISMED).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of THEMIS MEDICARE (THEMISMED)?
The current share price of THEMIS MEDICARE (THEMISMED) is ₹128.25. Today, the stock has declined by ₹3.82 (2.89%), trading in a range of ₹126.16 to ₹132.02. The stock opened at ₹132.02 with a trading volume of 1,10,605 shares.
02Is THEMIS MEDICARE stock a good investment for long-term?
THEMIS MEDICARE can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,187.17 Cr., P/E ratio of 30.51, ROE of -4.71%, and ROCE of -0.63%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of THEMIS MEDICARE stock?
The 52-week high price of THEMIS MEDICARE (THEMISMED) is ₹148.00, while the 52-week low is ₹64.95. Currently trading at ₹128.25, the stock is 97.46% above its 52-week low and 13.34% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy THEMIS MEDICARE stock at the current price?
Whether to buy THEMIS MEDICARE stock at ₹128.25 depends on multiple factors. The stock is currently trading with a P/E ratio of 30.51 and P/B ratio of 3.06. Today's performance shows a loss of 2.89%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of THEMIS MEDICARE and when is the next dividend?
THEMIS MEDICARE offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹128.25, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of THEMIS MEDICARE?
THEMIS MEDICARE's key financial metrics include: P/E Ratio: 30.51, P/B Ratio: 3.06, ROE: -4.71%, ROCE: -0.63%, Dividend Yield: 0%, EPS: ₹3.12, Book Value: ₹43.28, and Debt-to-Equity: 0.33. The company's market cap stands at ₹1,187.17 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is THEMIS MEDICARE stock performing today in the market?
THEMIS MEDICARE stock opened at ₹132.02 and is currently trading at ₹128.25, showing a decline of ₹3.82 (2.89%). The intraday high is ₹132.02 and low is ₹126.16. The trading volume stands at 1,10,605 shares, indicating moderate market participation today.
08What is the P/E ratio of THEMIS MEDICARE and what does it indicate?
THEMIS MEDICARE has a Price-to-Earnings (P/E) ratio of 30.51, which means investors are willing to pay 30.51 for every ₹1 of earnings. With an EPS of ₹3.12, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about THEMIS MEDICARE (THEMISMED) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.